Juno Pharmaceuticals Canada (« Juno »), une société pharmaceutique canadienne spécialisée, annonce son partenariat avec Rosemont Pharmaceuticals (« Rosemont ») pour devenir son distributeur canadien exclusif. Rosemont est une entreprise établie au Royaume-Uni qui développe, fabrique et fournit des médicaments…
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced the sale to OMERS, one of Canada’s largest defined benefit pension plans, of 54.5% of Enanta’s future royalty payments from…
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI’s Board of…
MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a multi-target research collaboration and option licensing agreement with BioMarin Pharmaceutical Inc. The collaboration will allow for the discovery, and potential development and commercialization of RNAa therapeutic candidates…
NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced that Mindful Care, the first-ever same-day mental health company focused on providing urgent psychiatric care, has selected NextGen® Behavioral Health Suite to support its short- and long-term…
Veristat, une organisation mondiale de recherche clinique (CRO) à l’esprit scientifique, a félicité aujourd’hui HIPRA pour l’autorisation de mise sur le marché par l’Agence européenne des médicaments (EMA) et la Commission européenne de BIMERVAX®, un vaccin bivalent avec adjuvant basé sur les…
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of the receptor for advanced glycation end products (RAGE) as a…
Life Edit® Therapeutics Inc., an ElevateBio® company focused on next-generation gene editing technologies and therapeutics, today announced the presentation of the first preclinical data from the company’s Huntington’s disease program across three presentations at CHDI’s 18th Annual Huntington’s Disease Therapeutics Conference taking place…
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced several new Environmental, Social, and Governance (ESG) goals today, including targets related to carbon emissions and workforce diversity. These goals are outlined in the Company’s newly released “Change…
Albatroz Therapeutics, a biotechnology company targeting tissue remodeling to stop cancer growth and treat arthritis, today announced it has secured $3 million USD in funding led by Outram Bio and SEEDS Capital to accelerate the development of therapeutic antibodies against…
A biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to…
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing DecisionDx®-Melanoma can improve risk stratification over American Joint Committee on Cancer (AJCC) staging alone in patients with stage I…